0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Jaguar Health Seeks Partner To Fund And Execute The Development Commercialize Of Np300
News Feed
course image
  • 26 Nov 2024
  • Admin
  • News Article

Jaguar Health Seeks Partner to Fund and Execute the Development & Commercialize of NP300

Jaguar Health seeks partner to fund and execute the development & commercialize of NP300
Jaguar Health seeks partner to fund and execute the development & commercialize of NP300, a prescription drug candidate to treat general diarrhoea in dogs

Overview

Jaguar Health, Inc. (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhoea in dogs, in exchange for commercial rights to the product in the US.

About the Drug: NP300

  • NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhoea (CID) in dogs. 
  • NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.

Words from the CMO: Jaguar

  • We look forward to evaluating NP300 for treatment of general, non-infectious diarrhoea in dogs, and to identifying a partner organization to fund and execute development and commercialization of the product,"" said David Sesin, PhD, Jaguar's chief manufacturing officer. 
  • We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhoea in dogs as well. We estimate that US veterinarians see approximately six million annual cases of acute and chronic diarrhoea in dogs.

About Diarrhoea

  • Diarrhoea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there is currently no FDA-approved drug to treat canine diarrhoea. 
  • According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of US households owning a dog in 2024.
  • Devastating diarrhoea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs.

About Jaguar Health, Inc.

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhoea, urgency, bowel incontinence, and cramping pain.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form